ArticleACS chemical neuroscience2025
Machine Learning Model for Predicting Sertraline-like Activities and Its Impact on Cancer Chemosensitization.
Article in ACS chemical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Combination of Antidepressants and Chemotherapeutic Agents to Overcome P-Glycoprotein-Mediated Resistance in Cancer Patients: A Systematic Review.Medical sciences (Basel, Switzerland) · 2026Pooled it
- New Personalized Medicine Model for Medication Management.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) like sertraline are crucial in treating depression and anxiety disorders, and studies indicate their potential as chemosensitizers in cancer therapy. This research develops a machine-learning predictive model to identify novel compounds with sertraline-like antidepressant activity. We constructed and validated a customized machine-learning model to predict SSRI activity in new compounds. By applying feature engineering to the chemical structures and bioactivity data of sertraline and its analogs, we trained multiple machine-learning algorithms. Through extensive comparative analysis, we found that the support vector machine (SVM) model demonstrated exceptional performance, achieving an accuracy rate of up to 93%. By further optimizing and integrating the SVM model, we successfully enhanced its accuracy, reaching an impressive 95% capability in predicting more active SSRI compounds. This study successfully developed a targeted, rapid, and efficient machine learning model capable of accurately predicting SSRI activity. The model serves as a valuable tool for rapidly screening novel SSRI drug candidates with superior activity, bringing immense value to the field of drug development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.